GlassScriptPhysician profile
Srinath Kadimi
NPI 1730144734
$31,512.81
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,488 · 2020: $5,455 · 2021: $11K · 2022: $7,398 · 2023: $28.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,819.81 | 2021-2023 | |
| Allergan, INC. | $7,177.84 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $2,942.65 | 2019-2020 | |
| Eisai INC. | $1,270.11 | 2019 | |
| Medtronic USA, INC. | $580.05 | 2019 | |
| Biogen, INC. | $394.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $298.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $236.60 | 2019 | |
| Emd Serono, INC. | $226.80 | 2019 | |
| Ucb, INC. | $151.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.65 | 2019 | |
| Acorda Therapeutics, INC | $126.98 | 2019 | |
| Adamas Pharmaceuticals, INC. | $121.45 | 2019 | |
| Mdd US Operations, LLC | $86.76 | 2019 | |
| Lundbeck LLC | $79.40 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $66.08 | 2019 | |
| Genzyme Corporation | $64.52 | 2019 | |
| Assertio Therapeutics, INC. | $62.56 | 2019 | |
| Acadia Pharmaceuticals INC | $59.15 | 2019 | |
| Alnylam Pharmaceuticals INC. | $56.54 | 2019 | |
| Promius Pharma LLC | $56.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $52.74 | 2019 | |
| Vertical Pharmaceuticals, LLC | $49.21 | 2019 | |
| Avanir Pharmaceuticals, INC. | $49.20 | 2019 | |
| Amneal Pharmaceuticals LLC | $47.98 | 2019 | |
| Boston Scientific Corporation | $44.93 | 2019 | |
| Akcea Therapeutics, INC. | $42.23 | 2019 | |
| Csl Behring | $38.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Pfizer INC. | $25.58 | 2019 | |
| Amgen INC. | $23.36 | 2019 | |
| Bausch Health US, LLC | $19.91 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.68 | 2019 | |
| Neurocrine Biosciences, INC. | $19.44 | 2019 | |
| Grifols USA, LLC | $13.01 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.90 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.73 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinath Kadimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.